Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1268 | Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol Wiki | 0.38 |
| drug514 | Blood for pharmacokinetic samples Wiki | 0.38 |
| drug2733 | Quantitative analysis of SARS-CoV-2 antibodies Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug874 | Connor-Davidson Resilience Scale 10 items (CD-RISC 10) Wiki | 0.38 |
| drug513 | Blood for anti-drug antibody (ADA) Wiki | 0.38 |
| drug2164 | Nasopharyngeal, oropharyngeal, or saliva swab Wiki | 0.38 |
| drug3051 | Sars-Cov-2 serology Wiki | 0.38 |
| drug554 | Brief Psychiatric Rating Scale Wiki | 0.38 |
| drug1022 | Depression, Anxiety and Stress Scale Wiki | 0.38 |
| drug2142 | NT-I7 Wiki | 0.38 |
| drug515 | Blood for research purposes Wiki | 0.38 |
| drug1641 | Impact of Event Scale-Revised Wiki | 0.38 |
| drug2956 | SARS-CoV-2 diagnostic rapid test Wiki | 0.27 |
| drug2327 | Online Survey Wiki | 0.17 |
| drug895 | Convalescent Plasma Wiki | 0.07 |
| drug2505 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000066553 | Problem Behavior NIH | 1.00 |
| D001523 | Mental Disorders NIH | 0.37 |
| D004194 | Disease NIH | 0.18 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009461 | Neurologic Manifestations NIH | 0.17 |
| D002908 | Chronic Disease NIH | 0.10 |
| D013315 | Stress, Psychological NIH | 0.07 |
| D002318 | Cardiovascular Diseases NIH | 0.07 |
| D040921 | Stress Disorders, Traumatic NIH | 0.07 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.06 |
| D001008 | Anxiety Disorders NIH | 0.06 |
| D016638 | Critical Illness NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.07 |
Navigate: Correlations HPO
There are 7 clinical trials
The Covid-19 pandemic in Indonesia makes several changes in daily living. The Indonesian government suggests that everyone should stay at home by implements the work from home and school from home. Therefore, the issues related with Covid-19 are also worrying such as death because of the infection, virus transmission, doing everything from home such as Friday praying for Moslem, Sunday service at home, etc. People is anxious whenever meeting people because they are not really understand whether people is infected or not. Therefore, this study tries to identify the impact of Covid-19 pandemic in Indonesia towards mental well-being of the community.
Description: The depression symptoms assessed by Patient Health Queationnaire-9 Scale. The range is 0 -27, the highest score means the highest depresive
Measure: Depression Time: up to 5 minutesDescription: The anxiety symptoms assessed by Generalized Anxiety Disorder -7 Scale. It is consists of 7 item with ranged score 0 -21. The highest score means the highest anxiety
Measure: Anxiety symptoms Time: up to 5 minutesDescription: The stress related problems assessed by Self Reporting Questionnaire-20 Scale. The range is 0 -20, the highest score means the highest mental health problems
Measure: Stress related problems Time: up to 7 minutesDescription: Behavior and emotional problem among children and adolescents assessed by Strength and Difficulties Questionnaire. SDQ consists of 25 statements, the score is ranged from 0 - 60. The highest score means the highest problems
Measure: Behavior and emotional problem among children and adolescents Time: up to 5 minutesGiven the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with psychiatric disorders and suspected of infection, hospitalized in a specific unit, at the psychiatric, somatic and pharmacological level.
Description: total severity score from the Impact of Event Scale-Revised (IES-R)
Measure: impact of the COVID-19 pandemic on psychiatric symptomatology Time: through study completion, an average of 2 yearCovid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.
Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19
Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19 Time: 12 monthsDescription: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases
Measure: Progression of pre-existing neurological or psychiatric pathologies Time: 12 monthsA dynamic analytical tool is being implemented to monitor the health, psychosocial and economic impacts of the COVID-19 pandemic as the crisis unfolds. A longitudinal survey is distributed via a network of hospitals, provincial/national organizations and web platforms. The survey information can be linked to provincial health administrative data and metrics derived from social media activity based on artificial intelligence methods. Targeted questions are included for critical populations such as healthcare workers and people with chronic illnesses.
Description: Cohen's Perceived Stress Scale (scores ranged from 0 to 40, higher scores indicating worse stress)
Measure: Mental health - Stress Time: through study completion, estimated to 8 monthsDescription: Generalized Anxiety Disorder Scale (scores ranged from 0 to 21, higher scores indicating worse anxiety)
Measure: Mental health - Anxiety Time: through study completion, estimated to 8 monthsDescription: Quick Inventory of Depressive Symptomatology-Self-report, short version (scores ranged from 0 to 27, higher scores indicating worse depression)
Measure: Mental health - Depression Time: through study completion, estimated to 8 monthsDescription: Measure of Moral Distress - Healthcare Professionals (scores ranged from 0 to 432, higher scores indicating worse moral distress)
Measure: Moral distress in healthcare workers Time: through study completion, estimated to 8 monthsDescription: Rushton Moral Resilience Scale (scores ranged from 1 to 4, higher scores indicating more resiliency)
Measure: Moral resilience in healthcare workers Time: through study completion, estimated to 8 monthsDescription: Frequency of interacting with other people (daily, weekly, monthly, less often than monthly)
Measure: Social life Time: through study completion, estimated to 8 monthsDescription: Fever, Cough, Difficulty breathing or shortness of breath, Tiredness, Aches and pains, Nasal congestion, Runny nose, Sore throat, Diarrhea (Mild Moderate, Severe, N/A)
Measure: COVID-9 symptoms Time: through study completion, estimated to 8 monthsDescription: Mortality (Yes/No): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Adverse health long-term outcome Time: 5 years before the outbreak and two years afterDescription: Hospitalizations (total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - Inpatient Time: 5 years before the outbreak and two years afterDescription: Emergency Department visits (Total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - ER Time: 5 years before the outbreak and two years afterDescription: Outpatient visits: https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - Outpatient Time: 5 years before the outbreak and two years afterDescription: Pittsburgh Sleep Quality Index (scores ranged from 0 to 21, higher scores indicating worse sleep disturbances)
Measure: Sleep Time: through study completion, estimated to 8 monthsThe aim of this study is to measure current affective symptoms and psychological distress in individuals with severe mental illness during the COVID-19 pandemic using an online questionnaire survey. In addition, this study aims at identifying individual beliefs, sleep quality, attitudes concerning the virus, the adherence to the measures, believing processes, and coping strategies/resilience patterns referring to COVID-19 in different study centers.
Description: Brief Symptom Inventory-18 with higher scores meaning a worse outcome (more depression, anxiety and somatization); Each item is weighted on a 0-4 interval scale; Minimum = 0, Maximum = 72)
Measure: Global symptom load (Anxiety, Somatisation, Depression, Global Symptom Index) Time: 1 yearDescription: Beck Depression Inventory-II with higher scores mean a worse Outcome (more depressive Symptoms; each item is weighted on a 0-3 interval scale; Minimum = 0, Maximum = 63)
Measure: Depressive symptoms Time: 1 yearDescription: Pittsburgh Sleep Quality Index (PSQI) with higher scores mean a worse Outcome (more sleeping disturbances; Each item is weighted on a 0-3 interval scale; Minimum = 0, Maximum = 63)
Measure: Sleep disorders and Sleep Quality Time: 1 yearDescription: Lifestyle Questions including physical activity, eating behavior, substance use, smoking
Measure: Life style changes Time: 1 yearDescription: Food Craving Inventory (FCI) with higher scores mean a worse Outcome (more Food craving; Each item is weighted on a 0-4 interval scale; Minimum = 0, Maximum = 112)
Measure: Food Craving Time: 1 yearDescription: COVID-19 questionnaire with higher scores meaning a worse Outcome (more fears and negative emotions; each item is weighted on a 0-10 interval scale)
Measure: COVID-19 associated fears and emotional responses to the pandemic Time: 1 yearPrimary objective is to evaluate the feasibility of delivering an online early Eye Movement Desensitisation Reprocessing (EMDR) Recent Traumatic Events Protocol (R-TEP) to patients who have survived Covid-19 related critical illness, within the context of a randomised controlled trial (RCT). This will inform the design of a future RCT investigating the effectiveness of EMDR R-TEP in reducing psychological symptoms, for adult survivors of intensive care.
Description: Feasibility will be determined by the following measures: Able to recruit >30% of eligible patients approached Complete early EMDR intervention programme in 75% or more of trial participants randomised to intervention. Protocol adherence Assignment of causality of serious events will be assessed by the chief investigator. Events attributable to trial procedures will be reviewed by trial management board, study sponsor and the research ethics committee, in order to determine ongoing feasibility. Outcome measures completed in 75% or more of trial participants
Measure: Feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints Time: 12 monthsDescription: The PTSD Checklist-Civilian Version (PCL-C) is a validated, standardised self-reporting questionnaire for PTSD comprising of 17 items that correspond to key PTSD symptoms
Measure: Post-Traumatic stress disorder Time: 6 months post-hospital dischargeDescription: Hospital Anxiety and Depression Scale (HADS) is a 14-item, self-reported measure with 7-items relating to symptoms of anxiety and 7-items relating to depression
Measure: Anxiety and depression Time: 6 monthsDescription: Montreal Cognitive Assessment (MoCA) is a validated tool, used to detect cogntive impairment
Measure: Cognitive function Time: 6 months post-hospital dischargeDescription: EQ5D -5L comprises five quality-of-life dimensions; mobility, self-care, usual activities, pain/discomfort andanxiety/depression.
Measure: Health Related Quality of Life Time: 6 months post-hospital dischargeDescription: WHODAS 2.0 is a generic assessment tool that produces standarised disability levels and profiles
Measure: Health and disability Time: 6 months post-hospital dischargeDescription: Wrist worn physical activity monitoring
Measure: Physical activity Time: 6 months post-hospital dischargeDescription: Patient generated subjective global assessment
Measure: Nutritional status Time: 6 months post-hospital dischargeThis observational study aims at Assessment of the prevalence and types Psychiatric disturbances that affects patients with COVID-19 infection with and without previous psychiatric diseases. in addition to, Assessment of the types of Psychiatric disturbances in patients with COVID-19 infection in correlation to age, disease severity, co-morbid conditions and treatments applied
Description: The General Health Questionnaire: To measure psychiatric well-being. Taylor Manifest Anxiety Scale: To determine the level of anxiety. Beck Depression Inventory: To assess symptoms of depression. The Brief-COPE scale: To assess coping responses. These questionnaires are combined in one questionnaire filled by the patients. it needs from 15-20 minutes.
Measure: Psychiatric well-being, level of anxiety, symptoms of depression and coping strategies questionnaire Time: 3 monthsDescription: prevalence of each type and correlation with age, disease severity, co-morbid conditions and treatments applied
Measure: Prevalence and types of Psychiatric disturbances in patients with COVID-19 infection Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports